Category:

This $1.2 Trillion Investment Is Transforming America (And Making Investors Rich)

Posted on by slightbourne@noblecapitalmarkets.com

They said it would never happen – that partisan gridlock would prevent any major infrastructure overhaul. But against all odds, the Infrastructure Investment and Jobs Act of 2021 was signed into law, unleashing a $1.2 trillion torrent of funding to rebuild America’s crumbling roads, bridges, and waterways. Now, savvy investors are pouring money into the companies at the forefront of this generational construction boom. Are you positioned to profit from this massive infrastructure revival?

The Infrastructure Investment and Jobs Act of 2021, signed into law by President Biden in November 2021, represents a major step forward in addressing the nation’s aging infrastructure. With a price tag of $1.2 trillion, the bipartisan legislation aims to rebuild and modernize America’s transportation systems, water infrastructure, broadband networks, and more.

One of the key beneficiaries of this historic investment is the construction industry, which is poised to receive a significant boost from the influx of funding for infrastructure projects. Companies like NV5 Global (NVEE), a provider of professional and technical engineering services, Sterling Infrastructure (STRL), a leading heavy civil construction firm, and Construction Partners Inc. (ROAD), a civil infrastructure company focused on road construction and repair, are well-positioned to capitalize on the opportunities presented by the Infrastructure Act.

Sterling Infrastructure specializes in the construction and reconstruction of transportation and water infrastructure systems, making it a prime candidate for many of the projects funded by the act. With a focus on the southern United States, the Rocky Mountain, and Mid-Atlantic regions, the company is likely to see an uptick in demand for its services as states and municipalities work to upgrade their roads, bridges, and water systems.

Another sector that stands to benefit significantly from the Infrastructure Act is the dredging industry. Great Lakes Dredge & Dock Corporation (GLDD), the largest provider of dredging services in the United States, is poised to benefit from the increased investment in coastal protection projects, port deepening, and land reclamation efforts.

Dredging plays a crucial role in maintaining and improving navigable waterways, ensuring the efficient movement of goods and supporting coastal communities. With the Infrastructure Act allocating funds for port infrastructure and coastal resilience initiatives, GLDD’s expertise in these areas will be in high demand.

The Infrastructure Act not only provides a financial boost to these industries but also represents a commitment to addressing long-standing infrastructure challenges. For decades, the United States has underinvested in its infrastructure, leading to a backlog of repair and maintenance needs. The act aims to tackle this issue head-on, with funding allocated for projects ranging from highway rehabilitation and bridge replacements to the modernization of public transit systems and the expansion of broadband access.

The impacts of the Infrastructure Act are expected to extend beyond the construction and dredging industries. The revitalization of the nation’s infrastructure is anticipated to create numerous job opportunities, stimulate economic growth, and enhance the overall competitiveness of American businesses. Furthermore, the act’s emphasis on sustainability and resilience aims to ensure that the infrastructure investments made today will withstand the challenges of tomorrow, including the effects of climate change and natural disasters.

As the implementation of the Infrastructure Act progresses, companies are well-positioned to play a pivotal role in shaping the future of America’s infrastructure landscape. Their expertise and capabilities will be instrumental in transforming the nation’s transportation networks, water systems, and coastal defenses, ensuring that they are modernized and resilient for generations to come.

The Infrastructure Investment and Jobs Act of 2021 represents a significant milestone in addressing the nation’s infrastructure needs. By providing substantial funding and a strategic framework, the act has the potential to catalyze economic growth, enhance public safety, and improve the overall quality of life for millions of Americans.


Continuing Impact and Investment Opportunities

Nearly two years since its passage, the Infrastructure Act continues to ripple through the markets and infrastructure sector. As funding is disbursed and projects progress, companies involved in construction, engineering, and related services are experiencing heightened demand and growth opportunities.

Beyond individual stocks, investors seeking exposure to the infrastructure boom may consider investing in sector-specific ETFs or mutual funds. These vehicles offer diversified exposure to a basket of companies poised to benefit from the Infrastructure Act’s initiatives.

However, it’s essential for investors to conduct thorough research and due diligence before making any investment decisions. While the Infrastructure Act presents significant opportunities, the success of individual companies and projects may vary, and unforeseen challenges or delays could impact their performance.

Additionally, as the implementation of the act progresses, new opportunities may arise for companies operating in adjacent sectors or providing specialized services. For instance, companies specializing in sustainable construction practices or cutting-edge technologies like smart infrastructure solutions could potentially benefit from the act’s emphasis on resilience and innovation.

As the nation embarks on this ambitious infrastructure overhaul, the investment landscape is likely to evolve, presenting both challenges and opportunities for savvy investors. Those who can identify and capitalize on the emerging trends and companies poised for growth may be well-positioned to benefit from the transformative impact of the Infrastructure Investment and Jobs Act of 2021.

Want small cap opportunities delivered straight to your inbox?

Channelchek’s free newsletter will give you exclusive access to our expert research, news, and insights to help you make informed investment decisions.

Get Instant Access

Release – V2X Sites Earn Top Honors by Defense Information Systems Agency

Posted on by dburczyk@noblecapitalmarkets.com

Research News and Market Data on VVX

MCLEAN, Va., May 20, 2024 /PRNewswire/ — V2X, Inc. (NYSE: VVX) is proud to announce that multiple sites under its operations within the Department of Defense Information Network have been named Facility of the Year by the Defense Information Systems Agency (DISA). These awards recognize exceptional performance across all aspects of the programs.

The DISA Defense Information Systems Network (DISN) Facility of the Year recognizes outstanding DISN facilities for exemplary accomplishments, performance, and contributions made to enhance the effectiveness in which the Department of Defense Information Network is operated, secured, and managed.

Three V2X locations emerged as winners with an additional four earning recognition as runners-up. The three V2X locations were chosen as winners support the Operations, Maintenance and Supply-Europe (OPMAS-E) program, the Enterprise Legacy Voice and Information System (ELVIS) program and the Operations, Maintenance and Defense of Army Communications (OMDAC) program.  

“We are deeply honored by the recognition of multiple V2X locations and remain committed to our ongoing commitment to provide enhanced reliability and protection of vital DoD networks across the globe,” said Ken Shreves, Senior Vice President of Global Mission Solutions and Chief Service Delivery and Growth Officer at V2X. “The contributions of OPMAS, OMDAC, and ELVIS to the DISA mission are paramount, and we take great pride in their steadfast dedication to delivering around the clock mission critical IT and communications support in over 10 countries.”  

The Facility of the Year winners include:

  • Europe Red Switch (ELVIS)
  • Europe Facility Control Office (OPMAS-E)
  • DISA CENT Large Transmission (OMDAC)

The Facility of Year Runners-Up are:

  • Europe Small Ankara (ELVIS)
  • Europe Medium Mildenhall (ELVIS)
  • Europe Large Landstuhl (OPMAS-E)
  • Europe Red Switch Patch Barracks (OPMAS-E)

DISA is a combat support agency of the Department of Defense (DoD) and provides, operates, and assures command and control and information-sharing capabilities and a globally accessible enterprise information infrastructure in direct support to joint warfighters, national level leaders, and other mission and coalition partners across the full spectrum of military operations.

About V2X

V2X builds smart solutions designed to integrate physical and digital infrastructure – by aligning people, actions, and outputs. Our lifecycle solutions improve security, streamline logistics, and enhance readiness. The Company delivers a comprehensive suite of integrated solutions across the operations and logistics, aerospace, training, and technology markets to national security, defense, civilian and international clients. Our global team of approximately 16,000 employees brings innovation to every point in the mission lifecycle, from preparation to operations, to sustainment, as it tackles the most complex challenges with agility, grit, and dedication.

Media Contact
Angelica Spanos Deoudes
Director, Corporate Communications
Angelica.Deoudes@goV2X.com
571-338-5195

Investor Contact
Mike Smith, CFA
Vice President, Treasury, Corporate Development and Investor Relations
IR@goV2X.com
719-637-5773

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/v2x-sites-earn-top-honors-by-defense-information-systems-agency-302149793.html

SOURCE V2X, Inc.

Release – The GEO Group Announces Funding Extension for Adelanto ICE Processing Center Contract

Posted on by dburczyk@noblecapitalmarkets.com

Research News and Market Data on GEO

BOCA RATON, Fla.–(BUSINESS WIRE)–May 20, 2024– The GEO Group (NYSE: GEO) (“GEO”) announced today that U.S. Immigration and Customs Enforcement (“ICE”) announced that it plans to issue a task order for the GEO-owned 1,940-bed Adelanto ICE Processing Center in California (the “Adelanto Center”), which provides for continued funding through September 30, 2024.

GEO previously filed motions, on January 4, 2024, with the U.S. District Court, Central District of California, in the case of Roman v. Wolf, to Intervene and to Vacate several injunction orders (collectively the “Orders”) including an intake prohibition order issued more than three years ago, limiting the use of the Adelanto Center based on then-prevailing COVID-19 conditions. GEO was joined in its filings by three unions (collectively the “Unions”) representing over 350 employees at the Adelanto Center. Subsequently, on April 22, 2024, GEO and the Unions filed a renewed motion with the U.S. Court of Appeals for the Ninth Circuit to intervene in the case of Roman v. Wolf, with a proposed motion to stay the Orders. GEO and the Unions will continue to pursue legal action to protect GEO’s and the Unions’ interests, which include the Adelanto Center contract’s annualized revenues and the potential loss of jobs by 350-plus employees.

ICE and GEO entered into a 15-year contract on December 19, 2019, for the provision of secure residential housing and care at the Adelanto Center, consisting of a 5-year base period, ending on December 19, 2024, followed by two 5-year option periods. The Adelanto Center contract generates approximately $85 million in annualized revenues for GEO.

About The GEO Group

The GEO Group, Inc. (NYSE: GEO) is a leading diversified government service provider, specializing in design, financing, development, and support services for secure facilities, processing centers, and community reentry centers in the United States, Australia, South Africa, and the United Kingdom. GEO’s diversified services include enhanced in-custody rehabilitation and post-release support through the award-winning GEO Continuum of Care®, secure transportation, electronic monitoring, community-based programs, and correctional health and mental health care. GEO’s worldwide operations include the ownership and/or delivery of support services for 100 facilities totaling approximately 81,000 beds, including idle facilities and projects under development, with a workforce of up to approximately 18,000 employees.

Use of forward-looking statements

This news release may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements and any such forward-looking statements are qualified in their entirety by reference to the following cautionary statements. All forward-looking statements speak only as of the date of this news release and are based on current expectations and involve a number of assumptions, risks and uncertainties that could cause the actual results to differ materially from such forward-looking statements, including statements regarding GEO’s filings in the case of Roman v. Wolf,statements regarding the Orders, and statements regarding the Adelanto Center contract. Risks and uncertainties that could cause actual results to vary from current expectations and forward-looking statements contained in this press release include, but are not limited to, risk factors contained in GEO’s filings with the U.S. Securities and Exchange Commission, including its Form 10-K, 10-Q, and 8-K reports. GEO disclaims any obligation to update or revise any forward-looking statements.

Pablo E. Paez (866) 301 4436
Executive Vice President, Corporate Relations

Source: The GEO Group, Inc.

Snail (SNAL) – Patiently Waiting for the ARK

Posted on by cpereira@noblefcm.com


Monday, May 20, 2024

Snail is a leading, global independent developer and publisher of interactive digital entertainment for consumers around the world, with a premier portfolio of premium games designed for use on a variety of platforms, including consoles, PCs and mobile devices.

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Patrick McCann, CFA, Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Q1 results. The company reported Q1 revenue of $14.1 million, and adj. EBITDA loss of $1.9 million, both of which were lower than our estimates of $24.0 million and $2.8 million, respectively. Notably, the company deferred $5.5 million of revenue in the quarter, which contributed to the shortfall. We expect revenue deferrals and the technology gap to cause some noise in operating results during 2024.

Technology gap. Importantly, we believe there is a technology gap between ASA and some of the user base’s PC equipment, which dampened sales of the game. We believe the closing of the technology gap could also lead to a more steady sales profile of the game over a longer period of time as users upgrade their hardware and migrate to ASA.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Alliance Resource Partners (ARLP) – An Interesting Turn of Events

Posted on by cpereira@noblefcm.com


Monday, May 20, 2024

ARLP is a diversified natural resource company that generates operating and royalty income from coal produced by its mining complexes and royalty income from mineral interests it owns in strategic oil & gas producing regions in the United States, primarily the Permian, Anadarko and Williston basins. ARLP currently produces coal from seven mining complexes its subsidiaries operate in Illinois, Indiana, Kentucky, Maryland and West Virginia. ARLP also operates a coal loading terminal on the Ohio River at Mount Vernon, Indiana. ARLP markets its coal production to major domestic and international utilities and industrial users and is currently the second largest coal producer in the eastern United States. In addition, ARLP is positioning itself as an energy provider for the future by leveraging its core technology and operating competencies to make strategic investments in the fast growing energy and infrastructure transition.

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Location, location. Alliance is the largest coal producer in the eastern U.S. with operations in the Illinois Basin and Appalachia. The partnership produces a diverse range of thermal coals with high heat content and benefits from access to both domestic and export markets. With demand for electricity expected to grow, Alliance is well-positioned to increase its market share despite efforts to curb coal-fired generation and coal’s declining share of the electricity generation market. Closure dates for coal-fired power plants are being delayed due to growing energy demand and reliability concerns.

Trouble brewing in the Powder River Basin (PRB)? Last week the Bureau of Land Management (BLM) proposed ending federal coal leasing in the Powder River Basin. The PRB includes Wyoming and Montana and accounted for 44% of the coal produced in the United States in 2022. The Bureau expects coal production in Wyoming to continue through 2041 under existing leases. While we expect the ruling to be challenged, it underscores the uncertainty and challenges facing coal mining operations on federally leased lands. The BLM manages public land in the western United States. In our view, coal could turn into an increasingly scarce resource in the United States which could be supportive of pricing.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Dow Smashes Through 40,000 as Unstoppable Rally Reaches New Heights

Posted on by slightbourne@noblecapitalmarkets.com

In a feat cementing the relentless momentum of the historic bull market, the Dow Jones Industrial Average has obliterated the 40,000 milestone for the first time ever. The blue-chip index’s new record high represents the culmination of a stupendous 15-month surge, defying fears of an economic downturn while leaving skeptics grasping for explanations.

The Dow’s ascension through 40,000 highlights the astounding resilience fueling U.S. equities. Robust corporate profits, rapidly cooling inflation, and rising optimism over the Federal Reserve’s ability to orchestrate a “soft landing” have emboldened investors. Propelling the rally, expectations have solidified that the central bank is nearing the conclusion of its aggressive rate hiking campaign to subdue elevated prices.

Market pricing now reflects two quarter-point interest rate cuts likely by year-end, with overwhelming odds of the first reduction materializing as soon as September. The dovish pivot aligns with this week’s cooler-than-anticipated consumer price data, relieving pressure on the Fed to maintain its hawkish posture.

The Dow’s remarkable feat has been powered by heroic gains among its elite constituents throughout 2023. Semiconductor titan Nvidia has skyrocketed 94% higher amid the AI frenzy. Industrial titans like 3M, Salesforce, Boeing and Walgreens Boots Alliance have all tacked on over 20%. Even beleaguered First Republic Bank remains up 17% year-to-date despite its recent turmoil.

For investors, the Dow’s breach of 40,000 represents the proverbial pot of gold at the end of the rainbow. The milestone solidifies the “Goldilocks” scenario playing out of moderating inflation and resilient growth, providing a springboard for further gains as concerns over economic overheating fade. While risks remain of a potential inflationary resurgence, excessively tight labor conditions forcing more Fed hawkishness, or a hard landing, the prevailing mood is overwhelmingly bullish.

Stretched valuations, with the S&P 500 trading north of 20x forward earnings, represent a valid concern. But traders and Wall Street strategists remain steadfastly focused on embracing the upside, brushing aside such worries amid a torrent of positive price momentum and fundamentals. The Dow’s coronation at 40,000 is emblematic of this euphoric mindset.

For the record books, the Dow ultimately settled the session at 39,869.38, up over 19% year-to-date after reaching an intraday record of 40,038.87 before paring gains. While symbolic, the new milestone supremely underscores the dynamism and strength across Corporate America’s boardrooms and C-suites. With earnings continuing to impress amid the rate cutting pivot, many on Wall Street expect the stock market’s electrifying run to continue regaling investors.

Want small cap opportunities delivered straight to your inbox?

Channelchek’s free newsletter will give you exclusive access to our expert research, news, and insights to help you make informed investment decisions.

Get Instant Access

Release – GeoVax to Raise Approximately $1.3 Million of Gross Proceeds in Offering Priced At-the-Market

Posted on by aweinsoff@channelchek.com

Research News and Market Data on GOVX

 

Atlanta, GA, May 17, 2024 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it has entered into a definitive securities purchase agreement with a certain institutional investor for the purchase and sale of 802,844 shares of the Company’s common stock (or common stock equivalents) at a price of $1.68 per share in a registered direct offering priced at-the-market under Nasdaq rules.

In addition, in a concurrent private placement, the Company will issue to the investor warrants to purchase up to 1,605,688 shares of common stock. The warrants have an exercise price of $1.68 per share, will be exercisable immediately following the date of issuance and will have a term of five years following the date of issuance.

Roth Capital Partners is acting as the exclusive placement agent for the offering.

The gross proceeds to the Company from this offering are expected to be approximately $1.3 million, before deducting the placement agent’s fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes. The closing of the offering is expected to occur on or about May 21, 2024, subject to the satisfaction of customary closing conditions.

The shares in the offering described above are being offered by the Company pursuant to a ‘shelf’ registration statement on Form S-3 (File No. 277585) previously filed with the Securities and Exchange Commission (the ‘SEC’) and declared effective by the SEC on March 13, 2024. The offering is being made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement, relating to the offering that will be filed with the SEC. Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained, when available, on the SEC’s website at http://www.sec.gov or by contacting Roth Capital Partners, LLC at 888 San Clemente Drive, Newport Beach CA 92660, by phone at (800) 678-9147 or by accessing the SEC’s website, www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel therapies and vaccines for solid tumor cancers and many of the world’s most threatening infectious diseases. The company’s lead program in oncology is a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, which recently completed enrollment in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax’s lead infectious disease candidate is GEO-CM04S1, a next-generation Covid-19 vaccine targeting high-risk immunocompromised patient populations. Currently in three Phase 2 clinical trials, GEO-CM04S1 is being evaluated as a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized Covid-19 vaccines are insufficient, and as a booster vaccine in patients with chronic lymphocytic leukemia (CLL). In addition, GEO-CM04S1 is in a Phase 2 clinical trial evaluating the vaccine as a more robust, durable Covid-19 booster among healthy patients who previously received the mRNA vaccines. GeoVax has a leadership team who have driven significant value creation across multiple life science companies over the past several decades. For more information, visit our website: www.geovax.com.

Forward-Looking Statements

This release contains forward-looking statements regarding GeoVax’s business plans. The words “believe,” “look forward to,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax’s immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax’s viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax’s immuno-oncology products and preventative vaccines will be safe for human use, GeoVax’s vaccines will effectively prevent targeted infections in humans, GeoVax’s immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax’s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.

Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. 

Company Contact:                   Investor Relations Contact:                  Media Contact:
info@geovax.com austin.murtagh@sternir.com sr@roberts-communications.com 
678-384-7220 212-698-8696 202-779-0929

Schwazze (SHWZ) – In for the Long Haul

Posted on by cpereira@noblefcm.com


Friday, May 17, 2024

Schwazze (OTCQX:SHWZ, NEO:SHWZ) is building a premier vertically integrated regional cannabis company with assets in Colorado and New Mexico and will continue to take its operating system to other states where it can develop a differentiated regional leadership position. Schwazze is the parent company of a portfolio of leading cannabis businesses and brands spanning seed to sale. The Company is committed to unlocking the full potential of the cannabis plant to improve the human condition. Schwazze is anchored by a high-performance culture that combines customer-centric thinking and data science to test, measure, and drive decisions and outcomes. The Company’s leadership team has deep expertise in retailing, wholesaling, and building consumer brands at Fortune 500 companies as well as in the cannabis sector. Schwazze is passionate about making a difference in our communities, promoting diversity and inclusion, and doing our part to incorporate climate-conscious best practices.

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

1Q24 Results. Revenue of $41.6 million was up 4% y-o-y, driven by new store growth. Gross margin declined to 43.1% from 54.6% due to pricing pressure in New Mexico and a higher mix of lower margined medical sales. Schwazze reported an operating loss of $2.7 million compared to $5.6 million of operating profit in 1Q23. GAAP net loss totaled $18.2 million, or a loss of $0.24/sh, versus essentially breakeven last year. We had estimated revenue of $42.5 million and a net loss of $11.6 million, or a loss of $0.16/sh.

Environment Still Challenging. The Colorado and New Mexico markets remain some of the most competitive cannabis markets in the country. A supply/demand situation still coming into balance and too many retail locations will continue to impact both markets in the near-term.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Bit Digital (BTBT) – AI Showing its Impact

Posted on by cpereira@noblefcm.com


Friday, May 17, 2024

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

AI Adding to Growth. Total revenue for the first quarter was $30.3 million compared to $8.3 million in the prior year. This surpassed our $23.5 million estimate, as a higher bitcoin price and the Company’s inclusion of AI revenue led to the increase. The AI revenue comes from the Company’s anchor AI contract with expected annualized revenue of $50 million. We believe the AI contract provides an alternative revenue stream non-correlated to the cryptocurrency market.

Potential for More Soon. Although the $50 million contract is in place, earlier in the year Bit Digital received a proposal for an expansion of its contract. With the expansion, the proposal calls for an additional 2,048 GPUs on top of the 2,048 GPUs already in the contract, effectively doubling revenue to $100 million. The Company is currently in talks with the client on the terms of the expansion and we expect an announcement in the coming weeks.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Crescent Shells Out $2.1 Billion for Massive Eagle Ford Upgrade

Posted on by slightbourne@noblecapitalmarkets.com

In a transformative transaction for the U.S. shale industry, Crescent Energy Company has agreed to acquire rival Eagle Ford producer SilverBow Resources in an all-stock deal valued at $2.1 billion. The combination solidifies Crescent’s position as a leading player in the prolific Eagle Ford basin of South Texas, creating the second largest operator in the region.

The deal significantly bolsters Crescent’s scale and low-cost inventory. SilverBow shareholders can elect to receive 3.125 Crescent shares for each SilverBow share owned, or opt for $38 per share in cash up to a $400 million cap. Post-closing, expected in Q3 2024, existing Crescent investors will own between 69-79% of the combined entity.

The merged company boasts imposing production of around 250,000 boe/d from a complementary portfolio of high-quality, long-life assets spanning the Eagle Ford and Uinta basins. This large-scale, high-margin asset base underpins robust free cash flow generation backed by a deep inventory of high-return drilling locations to drive compelling growth.

For Crescent, the deal achieves increased scale and premiumization of its portfolio through SilverBow’s attractive Eagle Ford position assembled over 30 years in the region. The combination enhances corporate returns through $65-$100 million of expected annual synergies from combined operating efficiencies and cost of capital benefits.

Crescent characterizes the transaction as highly accretive on all key per share metrics. It aligns with the company’s proven strategy of pursuing disciplined acquisitions at attractive valuations to augment its free cash flow, production, and inventory depth. Maintaining a fortress investment-grade balance sheet post-merger affords financial flexibility to further consolidate the fragmented shale landscape.

The deal represents a compelling value proposition for SilverBow shareholders. They gain exposure to Crescent’s larger-scale diversified assets while participating in the upside from performance improvements, synergy realization, and further consolidation. Alternatively, investors can opt for immediate cash consideration at a premium.

Crescent’s leadership expressed high confidence in the strategic merits of the transaction. Chairman John Goff labeled it “a compelling transaction…creating a premier growth platform”, while CEO David Rockecharlie highlighted SilverBow’s “complementary and high-quality” Eagle Ford position enhancing Crescent’s “unique value proposition.”

The merger exemplifies the accelerating consolidation across the U.S. shale patch as producers pursue scale, streamlining, and consistent shareholder returns. Crescent emerges exceptionally well-positioned to lead this rationalization as a serial acquirer given its sector-leading free cash flow generation, returns philosophy, and strong balance sheet.

Investors evaluating opportunities in the energizing energy and natural resources space may be interested in Noble Capital Markets’ upcoming Emerging Growth Equity Conference in September, offering insights into prospective investments.

Want small cap opportunities delivered straight to your inbox?

Channelchek’s free newsletter will give you exclusive access to our expert research, news, and insights to help you make informed investment decisions.

Get Instant Access

This $850M Biotech Deal Could Disrupt the Atopic Dermatitis Market

Posted on by slightbourne@noblecapitalmarkets.com

In a strategic move to strengthen its dermatology portfolio, pharmaceutical giant Johnson & Johnson has agreed to acquire Proteologix, a privately-held biotech developing bispecific antibody therapies for inflammatory skin diseases like atopic dermatitis. The $850 million all-cash deal gives J&J access to promising clinical and preclinical stage assets.

The crown jewel of the acquisition is Proteologix’s lead candidate PX128, a Phase 1-ready bispecific antibody targeting two key drivers of atopic dermatitis and asthma – interleukin-13 (IL-13) and thymic stromal lymphopoietin (TSLP). By simultaneously blocking these complementary inflammatory pathways, PX128 could provide a substantial efficacy boost over current monospecific antibody treatments.

Proteologix’s second asset, the preclinical bispecific PX130, goes after IL-13 and IL-22 for the treatment of moderate to severe atopic dermatitis. J&J cited the differentiated design of these dual-acting antibodies, highlighting their potential for infrequent, convenient dosing that could improve adherence.

The acquisition aligns with J&J’s strategic focus on building an immunology pipeline centered around bispecific antibodies for improved disease control across a range of inflammatory conditions.

Atopic dermatitis, a chronic inflammatory skin disease, impacts over 100 million adults worldwide, representing a massive market opportunity. However, up to 70% of patients fail to achieve remission on standard systemic treatments, underscoring a significant unmet need.

“We see an opportunity for best-in-disease efficacy for both PX128 and PX130,” said David Lee, global immunology therapeutic area head at J&J. The company believes the bispecifics could be game-changers for underserved patient subgroups by more comprehensively targeting the heterogenous drivers of atopic dermatitis.

The deal comes on the heels of positive Phase 3 data from Eli Lilly’s IL-13 antibody lebrikizumab in atopic dermatitis. After manufacturing setbacks, Lilly resubmitted its lebrikizumab filing in April and anticipates a decision later this year, setting up a potential commercial clash with J&J’s dual-acting antibodies down the road.

Proteologix, based in California, will be eligible for additional milestone payments on top of the $850 million upfront cash paid by J&J. The transaction, expected to close in mid-2024 pending regulatory approval, will fold in Proteologix’s other preclinical bispecific antibody programs focused on autoimmune diseases and cancer.

For J&J, the deal provides a promising path toward next-generation, differentiated therapies for the significant population of atopic dermatitis patients struggling with existing treatment options. Proteologix’s dual-acting bispecific antibodies represent potentially transformative medicines for a disease area that has proven stubbornly difficult to treat.

The acquisition reinforces J&J’s commitment to immunology and dermatology while bolstering its pipeline with innovative, clinically advanced assets that could drive future growth. As the atopic dermatitis market heats up, J&J has made a preemptive strike to secure a competitive edge through its newest biotech addition.

Want small cap opportunities delivered straight to your inbox?

Channelchek’s free newsletter will give you exclusive access to our expert research, news, and insights to help you make informed investment decisions.

Get Instant Access

Release – Traws Pharma Reports First Quarter 2024 Financial Results And Provides Business Update

Posted on by aweinsoff@channelchek.com

May 16, 2024

PDF Version

Completed acquisition of Trawsfynydd and concurrent $14 million Capital Raise

Excellent pipeline progress, led by candidates for COVID 19, influenza, and oncology programs

Poised to initiate Phase 2 studies in H2 2024 for our influenza candidate and
ritonavir-free COVID 19 protease inhibitor

NEWTOWN, Pa., May 16, 2024 (GLOBE NEWSWIRE) — Traws Pharma, Inc. (“Traws” or “Traws Pharma”), a clinical stage biopharmaceutical company developing oral small molecules for respiratory viral diseases and cancer, today announced financial results for the first quarter of 2024, and provided a business update.

“2024 has already been a transformative year for Traws Pharma to advance our portfolio of novel treatments for serious respiratory infections and oncology programs. We completed the acquisition of Trawsfynydd and concluded a concurrent $14 million private placement financing. In addition, we initiated first-in-human dosing for our COVID 19 product candidate, including completion of the first cohort dosing group. Furthermore, we completed the last dose escalation cohort for our CDK4+ inhibitor, narazaciclib,” stated Werner Cautreels, Ph.D., Chief Executive Officer of Traws Pharma. “We believe that we are poised to make even more meaningful progress in the second half of 2024, as we advance our influenza treatment and ritonavir-free protease inhibitor for COVID 19 into expanded Phase 1 dose escalation studies and begin Phase 2 development.”

“Based on the preclinical profile and early clinical data from our infectious disease candidates and narazaciclib, I am optimistic about the outlook for Traws’ portfolio and look forward to updating our investors with our progress through the year,” concluded Dr. Cautreels.

Traws Proprietary Portfolio Highlights:

TRX100 (tivoxavir marboxil): a cap-dependent endonuclease inhibitor for influenza: Phase 1

  • Targets the cap-dependent endonuclease of influenza and is a potent inhibitor of influenza virus replication including A and B strains
  • First Phase 1 study demonstrated safety and tolerability in healthy volunteers with pharmacokinetics and pharmacodynamics (PK/PD) data to support the potential use of a single oral dose for treatment or prophylaxis
  • We plan to initiate Phase 1 dose extension to evaluate one additional, higher dose prior to the initiation of Phase 2 studies in H2 2024. Topline data from the Phase 2 study are expected in H1 2025

TRX01 (ratutrelvir): a ritonavir-free Mpro protease inhibitor for COVID19: Phase 1

  • Potent oral inhibitor of SARS-CoV-2 Mpro (3CL protease), effective against the original, delta, and omicron variants of SARS-CoV-2, that does not require co-administration with ritonavir, reducing the risk of drug-drug interactions. Preclinical data support once-daily dosing for 10days which could overcome viral rebound seen with other agents.
  • We are in the process of conducting a Phase 1 first-in-human single ascending dose/multiple ascending dose (SAD/MAD) study in normal volunteers. The second dosing cohort is underway and topline data are expected H2 2024. A Phase 2 study is also planned to begin in H2 2024 in patients with moderate to severe COVID19. Topline data are expected H1 2025

Narazaciclib: CDK 4+ to treat solid tumors: Phase 1/2

  • Available preclinical and clinical data suggest that narazaciclib is active in numerous tumor types, inhibiting CDK 2/4/6, CSF1R and ARK 5/NUAK1. Preclinical studies also showed reduced neutropenia, as compared to palbociclib, and inhibition of palbociclib resistant cancer cells.
  • A dose escalation study to define the recommended Phase 2 dose (RP2D) recently enrolled the last cohort. A review of the clinical and PK/PD data is underway. We intend to utilize these data to define the clinical strategy, including selection of a lead indication and next steps in its development.

First Quarter 2024 Financial Results

Cash and cash equivalents as of March 31, 2024, were $16.4 million, compared with $20.8 million as of December 31, 2023.

In April 2024, the Company raised gross proceeds of $14 million from the sale of common and preferred stock to TPAV, LLC, an affiliate of Torrey Pines, and OrbiMed Private Investments VIII, LP, an affiliate of OrbiMed Advisors.

The Company believes that its cash and cash equivalents will be sufficient to fund ongoing clinical trials and business operations into the fourth quarter of 2024.

Revenue was fifty-six thousand dollars for the first quarter of 2024, consistent with the same period in 2023.

General and administrative (G&A) expenses were $3.4 million for the first quarter of 2024, compared with $2.1 million for the same period in 2023. The increase in G&A expenses was caused by higher legal and professional fees related to the Trawsfynydd acquisition on April 1, 2024, partially offset by lower bonus accrual as well as lower insurance, meeting, and public company expenses.

Research and development (R&D) expenses were $1.9 million for the first quarter of 2024, compared with $4.1 million for the same period in 2023. The decrease was primarily caused by lower costs related to narazaciclib drug substance and drug product manufacturing, a reduction in clinical development and consulting costs and lower personnel expenses due to lower bonus accrual.

Net loss for the first quarter of 2024 was $5.0 million, or $0.24 per share on 20.8 million weighted average shares outstanding, compared with a net loss of $5.8 million, or $0.28 per share for the same period in 2023, based on 20.8 million weighted average shares outstanding.

About Traws Pharma, Inc.

Traws Pharma is a clinical stage biopharmaceutical company developing oral small molecule therapies for the treatment of respiratory viral diseases and cancer. The viral respiratory disease program includes an oral inhibitor of the SARS-CoV-2 Mpro (3CL protease), ratutrelvir, and tivoxavir marboxil, a new oral antiviral drug candidate for influenza which targets the influenza cap-dependent endonuclease and has shown activity in cell-based assays against drug resistant viruses as well as against avian flu.

In the cancer program, Traws is developing the novel, proprietary multi-kinase CDK4-plus inhibitor narazaciclib potentially for refractory endometrial cancer and other solid tumor cancers. Narazaciclib targets pathways involved in the development of resistance to CDK inhibitors.

Traws Pharma is committed to delivering novel compounds for unmet medical needs using state-of-the-art drug development technology. With a focus on product safety and a commitment to patients in need or that are specifically vulnerable, we build solutions for important medical challenges, aiming to alleviate the burden of viral infections and cancer.

Forward-Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties including statements regarding the Phase 1 study of ratutrelvir in Australia and its design, timing and potential results and the timing of a planned Phase 2 study. Traws has attempted to identify forward-looking statements by terminology including “believes”, “estimates”, “anticipates”, “expects”, “plans”, “intends”, “may”, “could”, “might”, “will”, “should”, “preliminary”, “encouraging”, “approximately” or other words that convey uncertainty of future events or outcomes. Although Traws believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including the success and timing of Traws’ clinical trials, collaborations, market conditions and those discussed under the heading “Risk Factors” in Traws’ filings with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Traws undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Traws Pharma, Inc. Contact:
Mark Guerin
Traws Pharma, Inc.
267-759-3680
www.trawspharma.com

Investor Contact:
Bruce Mackle
LifeSci Advisors, LLC
646-889-1200
bmackle@lifesciadvisors.com

Release – Xcel Brands To Host First Quarter 2024 Earnings Call On May 20

Posted on by aweinsoff@channelchek.com

Research News and Market Data on XELB

May 16, 2024 at 8:01 AM EDT

PDF Version

NEW YORK, May 16, 2024 (GLOBE NEWSWIRE) — Xcel Brands, Inc. (NASDAQ: XELB) (“Xcel” or the “Company”), today announced that it will report its first quarter 2024 financial results on May 20, 2024. The Company will hold a conference call with the investment community on May 20, 2024, at 5:00 p.m. ET.

A webcast of the conference call will be available live on the Investor Relations section of Xcel’s website at https://xcelbrands.co/pages/events-and-presentations or directly at https://edge.media-server.com/mmc/p/r52mtx59.

Interested parties unable to access the conference call via the webcast may dial 800-715-9871 or 646-307-1963 and use the Conference ID 3975904. A replay of the webcast will be available on Xcel’s website.

About Xcel Brands

Xcel Brands, Inc. (NASDAQ: XELB) is a media and consumer products company engaged in the design, marketing, live streaming, social commerce sales of branded apparel, footwear, accessories, fine jewelry, home goods and other consumer products, and the acquisition of dynamic consumer lifestyle brands. Xcel was founded in 2011 with a vision to reimagine shopping, entertainment, and social media as one thing. Xcel owns the Judith Ripka, Halston, LOGO by Lori Goldstein, and C. Wonder by Christian Siriano brands and a minority stake in the Isaac Mizrahi brand. It also owns and manages the Longaberger brand through its controlling interest in Longaberger Licensing LLC and a 50% interest in a JV in TWRHLL (“Tower Hill”) by Christie Brinkley. Also Xcel owns a 30% interest in Orme, a short-form video market place. Xcel is pioneering a true modern consumer products sales strategy which includes the promotion and sale of products under its brands through interactive television, digital live-stream shopping, social commerce, brick-and-mortar retail, and e-commerce channels to be everywhere its customer’s shop. The company’s brands have generated in excess of $4 billion in retail sales via livestreaming in interactive television and digital channels alone. Headquartered in New York City, Xcel Brands is led by an executive team with significant live streaming, production, merchandising, design, marketing, retailing, and licensing experience, and a proven track record of success in elevating branded consumer products companies. For more information, visit www.xcelbrands.com.

For further information please contact:
Seth Burroughs
Xcel Brands
sburroughs@xcelbrands.com

Source: